Krystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024. In the quarter to June 2026, revenue grew 24.1%, EPS grew 39.1% and free cash flow grew 40.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow KRYS
Krystal Biotech, Inc. (KRYS) P/E ratio
As of 16 October 2026, Krystal Biotech, Inc. (KRYS) trades at a P/E ratio of 38.3×. Over the past ten years it has ranged from 0.0× (December 2023) to 996× (March 2024); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 34.8× | (31.09%) |
| FY2024 | 50.5× | (92.72%) |
| FY2023 | 694× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 44.9× | 34.83% |
| Mar 2026 | 33.3× | (4.28%) |
| Dec 2025 | 34.8× | 35.91% |
| Sep 2025 | 25.6× | (4.94%) |
| 8 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| IBRX ImmunityBio, Inc. compare | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. compare | n/m |
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| KRYS Krystal Biotech, Inc. | 38.3× |
| CAI Caris Life Sciences,�Inc. compare | 81.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 106× |
| BMRN BioMarin Pharmaceutical Inc. compare | 144× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)